United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - melphalan - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - melphalan - oral tablet - 2mg

United States - English - NLM (National Library of Medicine)

glaxo operations uk ltd - melphalan hydrochloride (unii: 1vxp4v453t) (melphalan - unii:q41or9510p) - melphalan 50 mg in 10 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - melphalan hydrochloride - powder and solvent for solution for injection - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: gelatin; peg-40 hydrogenated castor oil; corn glycerides; dl-alpha-tocopherol; titanium dioxide; iron oxide black; ethanol; glycerol; propylene glycol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - changes as described in the letter 23 december 1998 from b wall

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib, quantity: 2.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - dbl bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. dbl bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. dbl bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. dbl bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - dbl bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. dbl bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. dbl bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. dbl bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.